Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Danville Regional Medical Center
mi
from
Danville, VA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Nicholas Hospital
mi
from
Sheboygan, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Larry G Strieff MD Medical Corporation
mi
from
Oakland, CA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Larry G Strieff MD Medical Corporation
mi
from
Oakland, CA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Pismo Beach, CA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Joseph Hospital
mi
from
Denver, CO
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Straub Clinic and Hospital, Incorporated
mi
from
Honolulu, HI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Straub Clinic and Hospital, Incorporated
mi
from
Honolulu, HI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
OnCare Hawaii, Incorporated - Kuakini
mi
from
Honolulu, HI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
OnCare Hawaii, Incorporated - Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Kauai Medical Clinic
mi
from
Lihue, HI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Community Cancer Center
mi
from
Normal, IL
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
CCOP - Wichita
mi
from
Wichita, KA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Foote Memorial Hospital
mi
from
Jackson, MI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Foote Memorial Hospital
mi
from
Jackson, MI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Mercy Memorial Hospital - Monroe
mi
from
Monroe, MI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Mercy Memorial Hospital - Monroe
mi
from
Monroe, MI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. John Macomb Hospital
mi
from
Warren, MI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. John Macomb Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  7/31/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 7/31/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership
Status: Enrolling
Updated:  7/31/2015
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership
Status: Enrolling
Updated: 7/31/2015
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership
Status: Enrolling
Updated:  7/31/2015
Michigan Department of Community Health
mi
from
Lansing, MI
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership
Status: Enrolling
Updated: 7/31/2015
Michigan Department of Community Health
mi
from
Lansing, MI
Click here to add this to my saved trials
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated:  8/4/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated: 8/4/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated:  8/4/2015
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania
mi
from
Philadelphia, PA
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated: 8/4/2015
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated:  8/4/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated: 8/4/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated:  8/4/2015
NCI
mi
from
Rockville, MD
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated: 8/4/2015
NCI
mi
from
Rockville, MD
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Huntsville, AL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Mobile, AL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fayetteville, AR
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Bakersfield, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Greenbrae, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fairfield, CT
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Stamford, CT
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials